Dietary Requirement for Serum-Derived Bovine Immunoglobulins in the Clinical Management of Patients with Enteropathy

Digestive Diseases and Sciences

Volumn 60, Issue 1, 2015, Pages 13-23

  Petschow, Bryon W ^a   Burnett, Bruce P ^a   Shaw, Audrey L ^a   Weaver, Eric M ^a   Klein, Gerald L ^a  

^a Entera Health Inc   (United States)

Author keywords

Enteropathy; Gut barrier; Immunoglobulins; Inflammation; Nutrition; Plasma proteins

Indexed keywords

BOVINE IMMUNOGLOBULIN; IMMUNOGLOBULIN; SERUM GLOBULIN;

BREAST MILK; CLINICAL FEATURE; COLOSTRUM; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; ENTEROPATHY; ENVIRONMENTAL FACTOR; HOMEOSTASIS; HUMAN; IMMUNE DYSREGULATION; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE FUNCTION; LEAN BODY WEIGHT; LIPID ABSORPTION; NONHUMAN; NUTRITIONAL REQUIREMENT; NUTRITIONAL STATUS; REVIEW; WEIGHT GAIN; DIET THERAPY; DUODENUM; IMMUNOLOGY; INTESTINE; IRRITABLE COLON; MICROBIOLOGY;

DUODENUM; HIV ENTEROPATHY; HUMANS; IMMUNOGLOBULINS; INTESTINAL DISEASES; INTESTINES; IRRITABLE BOWEL SYNDROME; NUTRITIONAL STATUS; SERUM GLOBULINS;

EID: 84920508931     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3322-0     Document Type: Review

References (82)

1. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Bbiosci. 2009;14:2765–2778.
2. Kotler BM, Kerstetter JE, Insogna KL. Claudins, dietary milk proteins, and intestinal barrier regulation. Nutr Rev. 2013;71:60–65.
3. Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol. 2003;18:479–497.
4. Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res. 2013;69:42–51.
5. Coffey RD, Cromwell GL. Use of spray-dried animal plasma in diets for weanling pigs. Pig News Inf. 2001;22:39N–48N.
6. Torrallardona D. Spray dried animal plasma as an alternative to antibiotics in weanling pigs—a review. Asian-Australasian J Anim Sci. 2010;23:131–148.
7. Wilson D, Evans MD, Weaver E, et al. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013;6:49–60.
8. Asmuth DM, Ma ZM, Albanese A, et al. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS. 2013;27:2207–2217.
9. Prendergast A, Kelly P. Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg. 2012;86:756–763.
10. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009;44:879–888.
11. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:121–132.
12. Sharpstone D, Neild P, Crane R, et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut. 1999;45:70–76.
13. Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol. 2008;82:538–545.
14. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24:503–512.
15. Gasbarrini A, Lauritano EC, Garcovich M, et al. New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility. Eur Rev Med Pharmacol Sci. 2008;12:111–117.
16. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology. 2009;137:1912–1933.
17. Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Therapeut. 2012;36:1009–1031.
18. Keszthelyi D, Troost FJ, Masclee AA. Understanding the role of tryptophan and serotonin metabolism in gastrointestinal function. Neurogastroenterol Motil. 2009;21:1239–1249.
19. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159–176.
20. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2:416–422.
21. Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2013.
22. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163–173.
23. Spiller R, Garsed K. Infection, inflammation, and the irritable bowel syndrome. Digest Liver Dis. 2009;41:844–849.
24. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557–563.
25. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792–1801.
26. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301:G799–G807.
27. Jeffery IB, O’Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61:997–1006.
28. Gori A, Tincati C, Rizzardinin G, Torti C. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46:757–758.
29. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546–551.
30. Lidar M, Langevitz P, Shoenfeld Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. Isr Med Assoc J. 2009;11:558–563.
31. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13:260–270.
32. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731–16736.
33. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 2013;110:9066–9071.
34. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183–1189.
35. Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis. 2012;33:723–731.
36. Peuhkuri K, Vapaatalo H, Korpela R. Even low-grade inflammation impacts on small intestinal function. World J Gastroenterol. 2010;16:1057–1062.
37. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367:1626–1635.
38. Cummins PM. Occludin: one protein, many forms. Mol Cell Biol. 2012;32:242–250.
39. Prasad S, Mingrino R, Kaukinen K, et al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest. 2005;85:1139–1162.
40. Wardill HR, Bowen JM. Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care. 2013;7:155–161.
41. Brenchley JM, Douek DC. Microbial translocation across the GI tract. Ann Rev Immunol. 2012;30:149–173.
42. Watson CJ, Hoare CJ, Garrod DR, et al. Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. J Cell Sci. 2005;118:5221–5230.
43. Hedl M, Li J, Cho JH, Abraham C. Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci USA. 2007;104:19440–19445.
44. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–2045.
45. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463.
46. Yoo D, Lo W, Goodman S, et al. Interferon-gamma downregulates ion transport in murine small intestine cultured in vitro. Am J Physiol Gastrointest Liver Physiol. 2000;279:G1323–G1332.
47. Garcia-Herrera J, Marca MC, Brot-Laroche E, et al. Protein kinases, TNF-{alpha}, and proteasome contribute in the inhibition of fructose intestinal transport by sepsis in vivo. Am J Physiol Gastrointest Liver Physiol. 2008;294:G155–G164.
48. Pérez-Bosque A, Amat C, Polo J, et al. Spray-dried animal plasma prevents the effects of Staphylococcus aureus enterotoxin B on intestinal barrier function in weaned rats. J Nutr. 2006;136:2838–2843.
49. Demas GE, Chefer V, Talan MI, Nelson RJ. Metabolic costs of mounting an antigen-stimulated immune response in adult and aged C57BL/6J mice. Am J Physiol. 1997;273:R1631–R1637.
50. Johnson RW. Inhibition of growth by pro-inflammatory cytokines: an integrated view. J Anim Sci. 1997;75:1244–1255.
51. Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21:1391–1395.
52. Varcoe R, Haliday D, Tavill AS. Utilization of urea nitrogen for albumin synthesis in the stagnant loop syndrome. Gut. 1974;15:898–902.
53. Wanitschke R, Ammon HV. Effects of dihydroxy bile acids and hydroxy fatty acids on the absorption of oleic acid in the human jejunum. J Clin Invest. 1978;61:178–186.
54. Saito YA. The role of genetics in IBS. Gastroenterol Clin N Am. 2011;40:45–67.
55. Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10:1009–1015.
56. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr. 2004;134:479–482.
57. Bird JJ, Brown DR, Mullen AC, et al. Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998;9:229–237.
58. Peng L, He Z, Chen W, et al. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;61:37–41.
59. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469:543–547.
60. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr. 2010;156:S3–S7.
61. Development Petherick A. Mother’s milk: a rich opportunity. Nature. 2010;468:S5–S7.
62. Stockinger S, Hornef MW, Chassin C. Establishment of intestinal homeostasis during the neonatal period. Cell Mol Life Sci. 2011;68:3699–3712.
63. Morel PCH, Shollum LM, Buwalda TR. Digestibility of bovine immunoglobulin in the piglet. Manipulating Pig Production. In: Hennesey DP, Cranwell PD (eds) Proceedings of the Fifth Biennial Conference of the Australasian Pig Science Association (APSA), Canberra, ACT; 1995. p. 181.
64. Rodriguez C, Blanch F, Romano V, et al. Porcine immunoglobulins survival in the intestinal tract of adult dogs and cats fed dry food kibbles containing spray-dried porcine plasma (SDPP) or porcine immunoglobulin concentrate (PIC). Anim Feed Sci Technol. 2007;139:201–211.
65. Hanning RM, Drew M. Bovine immunoglobulin feeding trial. 1994 (data on file).
66. Begin F, Santizo MC, Peerson JM, et al. Effects of bovine serum concentrate, with or without supplemental micronutrients, on the growth, morbidity, and micronutrient status of young children in a low-income, peri-urban Guatemalan community. Eur J Clin Nutr. 2008;62:39–50.
67. Lembcke JL, Peerson JM, Brown KH. Acceptability, safety, and digestibility of spray-dried bovine serum added to diets of recovering malnourished children. J Pediatr Gastroenterol Nutr. 1997;25:381–384.
68. Peace RM, Campbell J, Polo J, et al. Spray-dried porcine plasma influences intestinal barrier function, inflammation, and diarrhea in weaned pigs. J Nutr. 2011;141:1312–1317.
69. Detzel CJ, Horgan A, Henderson AL, et al. Development of a co-culture model of the intestinal epithelium to study barrier function and immune exclusion by bovine IgG. J Parenter Enteral Nutr. 2014;38:146.127.
70. Corl BA, Harrell RJ, Moon HK, et al. Effect of animal plasma proteins on intestinal damage and recovery of neonatal pigs infected with rotavirus. J Nutr Biochem. 2007;18:778–784.
71. Bosi P, Casini L, Finamore A, et al. Spray-dried plasma improves growth performance and reduces inflammatory status of weaned pigs challenged with enterotoxigenic Escherichia coli K88. J Anim Sci. 2004;82:1764–1772.
72. Moretó M, Miró L, Maijó M, et al. Dietary supplementation with porcine plasma proteins reduce lymphocyte recruitment and cytokine and chemokine expression in a mouse model of spontaneous colitis. Gastroenterology. 2010;138:S-743.W1801.
73. Jiang H, Becker C, Przybyszewski J, MacDonald RS. Dietary immunoglobulins affect colon cytokines in mouse model of inflammatory bowel disease. FASEB J. 2010;24:720.1.
74. Pérez-Bosque A, Miró L, Polo J, et al. Dietary plasma protein supplements prevent the release of mucosal proinflammatory mediators in intestinal inflammation in rats. J Nutr. 2010;140:25–30.
75. Pérez-Bosque A, Miró L, Polo J, et al. Dietary plasma proteins modulate the immune response of diffuse gut-associated lymphoid tissue in rats challenged with Staphylococcus aureus enterotoxin B. J Nutr. 2008;138:533–537.
76. Weaver EM, Klein GL, DeVries BK, et al. Endotoxin Neutralization activity (ENA) of bovine plasma and bovine Immunoglobulin (IgG)-rich fractions as compared to human plasma. FASEB J. 2013;27:1079.58.
77. Navarro A, Eslava C, Garcia de la Torre G, et al. Common epitopes in LPS of different Enterobacteriaceae are associated with an immune response against Escherichia coli O157 in bovine serum samples. J Med Microbiol. 2007;56:1447–1454.
78. Asmuth DM, Stombaugh J, Ma ZM, et al. Changes in stool microbiota, bacterial translocation and mucosal immunity after oral serum-derived bovine immunoglobulin (SBI) administration. In: 20th Conference on Retroviruses and Opportunistic Infections (CROI); Mar 3–6; Atlanta, GA; 2013.
79. Asmuth DM, Ursell L, Ma ZM, et al. Duodenal lamina propria CD4+ T-lymphocyte (CD4+ LPL) increases following oral serum-derived bovine immunoglobulin (SBI) administration leads to reduced enterocyte damage and improved collagen turnover in HIV-enteropathy. Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2013.
80. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–1023.
81. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–180.
82. Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013;4:185.